EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Antitumor Activity of s-Triazine Derivatives: A Systematic Review

Qiuzi Dai, Qinsheng Sun, Xiaorong Ouyang, Jinyang Liu, Liye Jin, Ahao Liu, Binsheng He, Tingting Fan, Yuyang Jiang

Molecules · 23.05.2023 · 28 (11) · 4278

DOI: 10.3390/molecules28114278 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Molecules, online erschienen am 23.05.2023. Verfasst von Qiuzi Dai und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Hunan Provincial University Key Laboratory of the Fundamental and Clinical Research on Functional Nucleic Acid, Hunan Key Laboratory of the Resea…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Breast Neoplasms. Die Arbeit wurde bisher 106-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Natural Science Foundation of Hunan Province, Shenzhen Bay Laboratory Open Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

1,3,5-triazine derivatives, also called s-triazines, are a series of containing-nitrogen heterocyclic compounds that play an important role in anticancer drug design and development. To date, three s-triazine derivatives, including altretamine, gedatolisib, and enasidenib, have already been approved for refractory ovarian cancer, metastatic breast cancer, and leukemia therapy, respectively, demonstrating that the s-triazine core is a useful scaffold for the discovery of novel anticancer drugs. In this review, we mainly focus on s-triazines targeting topoisomerases, tyrosine kinases, phosphoinositide 3-kinases, NADP+-dependent isocitrate dehydrogenases, and cyclin-dependent kinases in diverse signaling pathways, which have been extensively studied. The medicinal chemistry of s-triazine derivatives as anticancer agents was summarized, including discovery, structure optimization, and biological applications. This review will provide a reference to inspire new and original discoveries.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBreast NeoplasmsHumansFemaleTriazinesDrug DesignStructure-Activity RelationshipDrug Screening Assays, Antitumor

Stichwörter der Autor:innen

antitumordrug targets-triazines

Substanzen

TriazinesAntineoplastic Agents

Autor:innen und Institutionen

  • The Hunan Provincial University Key Laboratory of the Fundamental and Clinical Research on Functional Nucleic Acid, Hunan Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Med…
  • State Key Laboratory of Chemical Oncogenomics, Tsinghua Shenzhen International Graduate School, Shenzhen 518055, China.
  • Institute of Biomedical Health Technology and Engineering, Shenzhen Bay Laboratory, Shenzhen 518132, China.
  • School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, China.

Förderung

  • the Natural Science Foundation of Hunan Province
  • Shenzhen Bay Laboratory Open Funding

Zitieren

APA

Dai, Q., Sun, Q., Ouyang, X., Liu, J., Jin, L., Liu, A., He, B., Fan, T., & Jiang, Y. (2023). Antitumor Activity of s-Triazine Derivatives: A Systematic Review. Molecules, 28(11), 4278. https://doi.org/10.3390/molecules28114278

Vancouver

Dai Q, Sun Q, Ouyang X, Liu J, Jin L, Liu A, et al. Antitumor Activity of s-Triazine Derivatives: A Systematic Review. Molecules. 2023;28(11):4278. doi:10.3390/molecules28114278

BibTeX
@article{Dai2023,
  author = {Dai, Qiuzi and Sun, Qinsheng and Ouyang, Xiaorong and Liu, Jinyang and Jin, Liye and Liu, Ahao and He, Binsheng and Fan, Tingting and Jiang, Yuyang},
  title = {Antitumor Activity of s-Triazine Derivatives: A Systematic Review},
  journal = {Molecules},
  year = {2023},
  volume = {28},
  number = {11},
  pages = {4278},
  doi = {10.3390/molecules28114278}
}
Kostenlos starten →